MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Active, not recruiting · NCT04895735 · Registry updated 2026-06-04Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Stomatognathic Diseases, adenocarcinoma, adenoid cystic carcinoma, carcinoma, epithelial neoplasm, mouth disorder, neoplasm, salivary gland cancer, salivary gland disorder | Active, not recruiting | Phase 2 | 2026-06-04 | NCT04895735 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic in Arizona | Scottsdale | United States | 191 |
| Mayo Clinic in Rochester | Rochester | United States | 687 |